SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.00+8.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (6307)5/10/2002 9:46:10 AM
From: Biomaven  Read Replies (3) of 52153
 
Certainly some of the current trading is being driven by people who don't know anything about biotech. As an example, VPHM just got hammered because (surprise!) the FDA came out with a non-approvable letter. (I just re-entered the stock in a small way this morning).

But until the NASD recovers I don't see much in the way of recovery for biotech stock prices either. In the way of fundamentals I see three key events - ASCO (but a lot of this may be in the market already), BGEN's Amevive AC meeting later this month and the Flumist application. I figure Amevive and Flumist are both too close to call.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News